Article

Latanoprost enhances lymphatic drainage in murine model

Latanoprost 0.005% (Xalatan, Pfizer), a prostaglandin analogue, stimulates lymphatic drainage in normal mouse eyes, said Alex Tam, MD, who presented the details of his mouse model and the implications of this research.

Fort Lauderdale, FL-Latanoprost 0.005% (Xalatan, Pfizer), a prostaglandin analogue, stimulates lymphatic drainage in normal mouse eyes, said Alex Tam, MD, who presented the details of his mouse model and the implications of this research.

“The existence of lymphatics in the eye has been questioned for the past century,” said Dr. Tam, of the Department of Ophthalmology & Vision Sciences, Laboratory Medicine & Pathobiology, University of Toronto.

In a previous study, he showed that there is a lymphatic system in the eye. In the current study, he and his colleagues tested if latanoprost enhances lymphatic drainage; 11 male pigmented mice treated with latanoprost and 11 control mice treated with artificial tears were injected in the left anterior chamber with Quantum dot nanocrystals, semiconductor nanoparticles. Hyperspectral fluorescence imaging using Maestro (CRi) was carried out before the injection and 5, 20, 40, and 70 minutes and 2, 6, and 24 hours after injection.

Before the animals were sacrificed, imaging was conducted to locate signals from the nanoparticles. The latanoprost-treated mice had a signal from the left neck early after injection (from 20 to 360 minutes). The earliest signal in the control mice was seen in most mice between 120 and 360 minutes. Immunofluorescence studies showed that the nanoparticles were in the subcapsular region of the left submandibular node in all mice. The signal intensity was increased in latanoprost-treated mice compared with the control mice.

Dr. Tam concluded that latanoprost enhances lymphatic drainage from the normal mouse eye. The lymphatics might be a new therapeutic target to improve fluid drainage from the eye.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.